Loss of Pten in the
O
varian cancer is a complex disease and remains the fifth most lethal cause of death by cancer in women. It is difficult to detect and hard to manage with current surgical and chemotherapeutic strategies (1, 2) . Among all human ovarian cancers (excluding germ cell cancer), granulosa cell tumors account for approximately 10%, whereas epithelial ovarian carcinomas (EOCs) account for approximately 90% of known tumors. EOCs are subdivided into four major classes based on histological criteria as well as more recent molecular signatures (2) . Approximately 70% of EOCs are serous adenocarcinomas followed by endometrioid, mucinous and clear cell cancers. EOC are also classified as low grade and high grade based on distinct pathogeneses, molecular phenotypes, and responses to conventional chemotherapy (1) (2) (3) (4) (5) . One distinguishing and relevant feature of low-grade and highgrade ovarian cancer is the expression of the tumor repressor protein 53 (TP53; or p53): almost all high-grade serous adenocarcinomas (96%) have TP53 mutations, whereas low-grade tumors express elevated levels of wildtype TP53 (6 -8) . Normal ovarian surface epithelial cells or fallopian epithelial cells, the potential origins of lowgrade serous ovarian carcinomas, do not normally express TP53 (9) . DNA sequencing analysis has shown that most low-grade serous carcinomas of the ovary carry wild-type TP53 (10, 11) . Based on immunohistochemistry analysis, low-grade ovarian serous carcinomas express wild-type TP53, although the expression is not as robust as mutated TP53 protein in high-grade serous ovarian carcinomas (7, 12) . Thus, it will be interesting to determine the functional role of wild-type TP53 expression in low-grade ovarian carcinomas. Understanding the functional roles of mutant vs. wild-type TP53 is of critical importance for developing new and more effective therapies for each cancer subtype.
The task of understanding the functions of TP53 is challenging because the responses of cells to TP53 are complex, context specific, and dependent on its activation status (13) (14) (15) . In addition, there is a complex interplay among phosphatase and tensin homolog deleted from chromosome 10, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, and TP53 in tumor development and progression (1, 2, 8) . Many studies in other normal and cancer cell types as well as in other tissues during embryogenesis and development document that wild-type TP53 controls diverse cellular processes including cell cycle arrest, senescence, apoptosis, DNA repair, cell migration, autophagy, metabolism, differentiation, and reprogramming (7, 16 -18) . Because of its predominant role in preventing propagation of damaged DNA and in inducing cell death, TP53 has become known as the guardian of the genome (19) . That mutations of TP53 are present in nearly 50% of all human cancers reinforces how critical the functions of this protein are to normal cell homeostasis. Due to this, restoration of TP53 is being investigated as a therapy for cancer treatment. Several recent animal studies document the effectiveness of restoring wild-type Trp53: it promotes regression of tumors containing wild-type Trp53 (20 -22) and suppresses tumor growth in cells containing mutant Trp53 (23) . Despite the presence of wild-type TP53 in low-grade serous ovarian cancer and the strikingly high prevalence of TP53 mutations in serous adenocarcinoma (24) , little is yet known about the functional roles of wild-type or mutant TP53 in human ovarian cancer cells.
Mouse models provide efficient, reproducible systems in which to analyze the specific functions of oncogenes and tumor suppressors in vivo. Recently we generated a mouse model in which disruption of the Pten gene in the Kras
G12D
;Amhr2-Cre strain leads to the development of low-grade serous, papillary adenocarcinomas at an early age and with 100% penetrance (8, 25) . We have shown further that the ovarian surface epithelial cells in these tumors express increased levels of wild-type TRP53 mRNA and protein (8) as is observed in human low-grade ovarian cancer (6, 7) . The Pten;Kras; (Trp53ϩ);Amhr2-Cre mutant mice therefore provide an ideal system in which to determine the functional roles of wild-type TRP53 in transformed serous adenocarcinoma cells that exhibit histological and functional similarities to human low-grade serous ovarian carcinomas. 
Materials and Methods

Animal procedures
Histology and immunohistochemistry
Ovaries were collected and fixed in 4% paraformaldehyde, embedded in paraffin, and processed by routine procedures for immunohistochemistry (25) of Cytokeratin 8 (ab59400; Abcam, Cambridge, MA) and TRP53 (sc-6243; Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Cell lines and isolation and culture of primary OSE cells
The HOC-7 cell line was derived from the malignant ascite of a patient with stage III low-grade adenocarcinoma of the ovary (28, 29) and contains wild-type TP53 as determined by sequencing. OSE cells were isolated and cultured as previously described (8) . 
Migration and adhesion assays
Inoculation of cells into syngenic mice
The 1 ϫ 10 6 mutant OSE cells were injected sc into wild-type mice with the same genetic background along with Matrigel (BD Biosciences) according to the manufacturer's protocol. Tumors were harvested and fixed in 4% paraformaldehyde after 20 d.
Real-time RT-PCR for mRNA and mature microRNA (miRNA)
Total RNA was isolated using the RNeasy minikit (QIAGEN, Germantown, MD) and treated with deoxyribonuclease I (DNA free; Ambion, Inc. Austin, TX) according to the manufacturer's instructions. cDNA was synthesized with Moloney murine leukemia virus reverse transcriptase (Invitrogen, Grand Island, NY) primed with random hexamers. Real-time PCR was performed using the Light Cycler DNA master SYBR Green I kit (Roche Applied Sciences, Nutley, NJ). Primers (Supplemental Table  1 , published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org) were used at a concentration of 0.25 M and MgCl 2 at 2.4 mM. Samples were denatured for 2 min at 95 C and then 35 cycles of 95 C for 15 sec, 60 C for 30 sec, and 72 C for 30 sec as previously described (25) . Data were normalized to RPL19 using the comparative cycle threshold method. Data are presented as the mean Ϯ SEM of a representative of at least three experiments performed in triplicate.
Small RNA required for detecting and measuring mature miRNA were extracted using the mirVANA miRNA isolation kit (Ambion) according to the manufacturer's instructions. For quantification of mature miRNA, the TaqMan miRNA assay kit (Applied Biosystems, Foster City, CA) was used according to the manufacturer's instructions.
Microarray
Total RNA was prepared using the RNeasy mini kit (QIAGEN) from OSE cells isolated from wild-type control, Pten fl/fl ; Kras 
Gene expression analysis
Results
TRP53 mediates the formation of elaborate papillary structures in low-grade serous adenocarcinoma tumors
Immunohistochemical staining for TRP53 shows that TRP53 is absent in the surface epithelial cells of normal ovaries (Fig. 1A) . In contrast, TRP53 is highly induced in the OSE papillary structures of low-grade ovarian tumors from Pten;Kras (TRP53ϩ) mice (Fig. 1A, middle column) as previously shown (8) . Immunostaining forTRP53 is absent in the nonpapillary OSE cell layer in ovaries of the Pten;Kras (Trp53Ϫ) mice confirming the absence of Trp53 mRNA expression (Fig. 1A, last column) . Histological sections from ovaries of control mice show that the ovarian surface epithelium is a single layer of mesoepithelial cells that stain for the epithelial-specific marker cytokeratin 8 (Fig. 1B) 1 , B and C, last column) providing evidence that wild-type TRP53 supports the formation of ovarian papillary structures in low-grade serous adenocarcinomas. The lack of papillary structures at later ages suggests Trp53 prevents progression of this phenotype (data not shown). The OSE cells were isolated and grown in culture to characterize the molecular and cellular effects of TRP53 (Fig. 1D) ras(Trp53ϩ) OSE cells ( Fig. 2A) 3A ) and in cells grown in Matrigel (Fig. 3B) . Similarly, the TRP53 targets mir-34a and mir-34c were up-regulated only in Trp53ϩ OSE cells (Fig. 3C) 
TRP53 regulates OSE tumor cell adherence, migration, and invasion
The Trp53Ϫ mutant cells were grown in soft agar to determine whether the cells are transformed. The Trp53ϩ and Trp53Ϫ mutant cells formed a similar number of colonies, indicating the Trp53Ϫ cells are transformed (Fig.  4A ). TRP53ϩ and TRP53Ϫ cells were also injected sc into syngeneic mice as another measure of transformation (Fig.  4B) . As seen previously, the TRP53ϩ cells formed tumors (8) and invaded the dermal and epidermal layers of the skin after 20 d. Similarly, the TRP53Ϫ cells formed tumors, confirming these cells are transformed. However, the tumors derived from the Trp53Ϫ cells were smaller and did not invade the dermal layer, indicating TRP53 mediates OSE cell tumor invasion in the Pten;Kras-(Trp53ϩ) model (Fig. 4 , B and C). To asses proliferation, OSE cells isolated from wild-type, Pten;Kras(Trp53ϩ), and Pten;Kras(Trp53Ϫ) ovaries were grown in culture for 2 d. As previously described, the Trp53ϩ mutant cells had a significantly higher proliferation rate compared with wild-type cells (Fig.  5A) . However, the proliferation rate in culture of cells lacking Trp53 was not altered, indicating that TRP53 is not obligatory in this context. To assess the impact of Trp53 on cell migration and adhesion, migration and adhesion assays were performed. Only a few wildtype cells had migratory activity, and no cells were attached to the cell culture dish 1 h after plating but were attached at 6 h (data not shown). In contrast, a large number of Trp53ϩ cells were migratory compared with wild-type cells (Fig. 5B) . Cell migration was decreased in the absence of Trp53, suggesting that TRP53 controls OSE tumor cell migration. Similar to migration, Trp53Ϫ cells were less adherent compared with Trp53ϩ mutant cells (Fig. 5C) . Thus, Trp53 appears to promote adhesion and migration of these transformed OSE cells in these contexts. Activation of TRP53 by nutlin-3a induces cell cycle arrest and apoptosis of Trp53؉ OSE tumor cells Similar to the tumor OSE cells in mice that develop low-grade serous adenocarcinoma, TP53 is elevated in tumor cells from human patients with low-grade serous adenocarcinoma (Fig. 6A) . To determine whether TRP53 is fully activated in the mutant OSE cells, the cells were exposed to the TRP53 activator nutlin-3a (Fig. 6B) . Nutlin-3a is a small molecule that disrupts the interactions of TRP53 with the E3 ubiquitin ligase mouse double minute-2 (MDM2) (34, 35) and thereby leads to TRP53 stabilization and increased activation. Indicative of elevated TRP53 activity, the expression of TRP53 target genes Mdm2 and those controlling the cell cycle arrest, p21 (Cdnk1a) and p16 (Cdnk2a), are elevated in nutlin-3a-treated cells. By contrast, the cell survival and DNA stability proteins Birc5 and Brca1, respectively, are decreased by nutlin3a. Nutlin-3a also induced the expression of the apoptosis mediators Perp and Puma. We also treated the human low-grade serous adenocarcinoma cell line HOC-7 with nutlin-3a to confirm this effect in human ovarian cancer cells that contain wild-type TP53. As shown, nutlin-3a induced the expression of P21, P16, MDM2, PERP, and PUMA in the HOC-7 cells. Nultin-3a did not similarly regulate these genes or cause cell cycle arrest in mouse Pten; Kras(Trp53Ϫ) cells or human SKOV3 ovarian cancer cells that lack Tp53 (Fig.  6C) . These results provide strong evidence that nutlin-3a may provide a novel therapy for low-grade serous ovarian carcinoma.
Discussion
The results of these studies document that the expression of Trp53 in the Pten;Kras mutant OSE cells controls the morphology, functional activity (adhesion and migration), and gene expression profiles in the mutant OSE cells. By selectively disrupting Trp53 in the Pten;Kras OSE cells, we have unveiled a novel and powerful role for wild-type TRP53 as a major promoter of ovarian cancer cell survival and differentiation that, to our knowledge, has not been previously identified. The Pten;Kras mutant OSE cells lacking Trp53   FIG. 6 . Nutlin-3a induces expression of cell cycle arrest genes and mediators of apoptosis in human and mouse cancer OSE cells that express wild-type TRP53 and Trp53, respectively. A, OSE cells from mouse and human serous adenocarcinoma express elevated levels of wild-type Trp53/TP53 as shown by RT-PCR. B, Nutlin-3a induces the expression of cell cycle control genes, DNA stability genes, and mediators of apoptosis in human and mouse serous adenocarcinoma OSE cells that express wild-type P53. C, Trp53/P53 is expressed at low levels and is not induced by nutin-3a in mouse Trp53Ϫ cells and human TP53Ϫ SKOV-3 cells.
are transformed yet are less adherent, migratory, and invasive in vivo and in vitro and exhibit a gene expression profile more like wild-type OSE cells (summarized in Fig  7) . These results provide a new paradigm: wild-type TRP53 does not preferentially induce apoptotic or senescent related genes in the Pten;Kras(Trp53ϩ) cells. Rather these cells express increased levels of genes regulating DNA repair, cell cycle progression, and proliferation and decreased levels of genes with putative tumor suppressor functions. In this regard, the role of wild-type TRP53 in the mutant Pten;Kras OSE cells appears to be similar to that in normal cells that are highly proliferative during embryogenesis and development (reviewed in Refs. 36 and 37) . In this scenario, the levels of TRP53 and its activity, presumably low, are compatible with cell proliferation, survival, migration, and differentiation. Perhaps more intriguing and of relevance to various mouse cancer models, gene expression profiling in the Simian virus 40 (SV40)-T-transformed breast, lung, and prostate cells shows that expression of many DNA repair and cell survival genes, such as Rad51, Brca1, Birc5, and Hells to name a few, are elevated (38) . These results combined with our observations suggest that although SV40T binds RB and TRP53 and has been presumed to inactivate them, there may be a sufficient low amount of active, wild-type TRP53 and/or RB to induce the expression of genes promoting proliferation and survival. Many of these genes have been shown to bind TP53 with high affinity compared with genes controlling apoptosis that bind TP53 with lower affinity (14, 15, 39, 40 (19) . Accordingly, when TRP53/TP53 activity was increased dramatically in the mouse and human mutant OSE cells in culture by exposure to nutlin-3a, TRP53/TP53 induced the expression of genes controlling cell cycle arrest and apoptosis and suppressed genes controlling DNA repair and survival. This major switch in gene expression by elevated TRP53 activity indicates clearly that the effects of endogenous wild-type TPR53 are dependent not only on the level of its expression but also acutely on its activation status. Therefore, activation of TP53 in vivo with nutlin-3a may provide a promising new therapy for managing low-grade serous ovarian cancer and other cancers in which wild-type TP53 is expressed by switching growth-promoting to growth-inhibitory pathways (6, 7, 42) . Because we have shown that the loss of Pten increases Trp53 (Ref. 8) and herein) and because others have shown that overexpression and activation of TRP53 can suppress phosphatidylinositol 3-kinase activity (43) , this feedback loop may be critical for increasing or suppressing tumor growth.
The results of these studies shed new light and thus may also help explain why the focus of TP53 as a tumor suppressor has overshadowed the results of studies showing that TP53 also promotes cell survival and proliferation. For example, the expression of some oncogenes in some tissues may cause DNA damage that not only leads to increased expression of Tp53 but may also lead to changes in cell function that promote a high level of TP53 activation. In this context, TP53 would induce cell cycle arrest and apoptosis. Furthermore, when cells are exposed to UV radiation and chemotoxic agents, TP53 expression and activation are increased to cause cell cycle arrest. However, when the ac-
FIG. 7.
In the absence of Trp53, Pten;Kras OSE cells are transformed yet do not differentiate into extensive papillary structures. Pten;Kras OSE tumor cells that express low levels of active TRP53 are similarly transformed yet form extensive papillary structures in addition to having increased migration and invasion properties in vitro and in vivo. Additional modifications are required for secondary tumors at distant sites. Nutlin-3a activation of TRP53 in transformed OSE cells triggers cell cycle arrest and apoptosis. Thus, activation of TP53 may provide an innovative therapeutic approach for low-grade serous adenocarcinomas and other cancers that express wild-type TP53.
tivation status of TP53 declines, it can again promote cell survival. This may be one mechanism by which cancer stem cells lead to the recurrence of ovarian cancer.
TRP53 also appears to regulate genes involved in adhesion and migration. The movement of cells in developing tissues and during tumor cell metastasis are likely similar multifactorial events that require tight control of many processes including cell proliferation, migration, changes in cell shape, and adhesion. Tumors in Trp53-depleted OSE cells do not metastasize, suggesting other signaling pathways are required (44) . However, although the data are limited, there is some evidence that TP53 regulates cell motility (26, 45, 46) . Our data suggest that TRP53 plays a role in cell adhesion and migration, yet other modifying events are required for growth of tumors at secondary sites.
In summary, the results of these studies document that TRP53 can promote ovarian cancer cell survival and the differentiation of OSE cell papillary structures. This, in addition to the evidence that TP53 is induced by oncogenes in many cancers and the emerging role for TP53 regulation of cell differentiation and self-renewal, emphasizes the relevance of the impact of timing of expression and degree of activity on TP53 action.
